Toronto, ON and Winnipeg, MB – Biopharmaceutical company Cangene Corporation says it is consolidating all research and development activities within its Winnipeg head office location. The reorganization means the company will suspend its R&D functions in its Mississauga office, resulting in a 4% reduction in staff.
The company says significant portion of the activities in its Mississauga R&D operation were related to a contract research project with the Apotex Group that is now concluded and to two products (Accretropin(TM) and Leucotropin(R)) that have been submitted for licensure. On-going responsibility for any additional development of these two products will be transferred to the Winnipeg group.
Non-R&D functions in Mississauga are unaffected by the consolidation.